Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes.
Facteurs de risqueMaladies auto-immunesLupus érythémateux
#2
L'âge influence-t-il le risque ?
Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans.
ÂgeRisqueLupus érythémateux
#3
Les antécédents médicaux jouent-ils un rôle ?
Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique.
Antécédents médicauxMaladies auto-immunesRisque
#4
Le stress peut-il être un facteur de risque ?
Oui, le stress peut exacerber les symptômes et augmenter le risque de complications.
StressRisqueComplications
#5
Y a-t-il des facteurs environnementaux ?
Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur.
EnvironnementMédicamentsFacteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes",
"headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-16",
"dateModified": "2025-04-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"url": "https://questionsmedicales.fr/mesh/D019774",
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"code": {
"@type": "MedicalCode",
"code": "D019774",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.113"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Inhibiteur lupique de la coagulation",
"alternateName": "Lupus Coagulation Inhibitor",
"code": {
"@type": "MedicalCode",
"code": "D016682",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Thomas Schmitz",
"url": "https://questionsmedicales.fr/author/Thomas%20Schmitz",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Charlotte A Bäuml",
"url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany."
}
},
{
"@type": "Person",
"name": "Diana Imhof",
"url": "https://questionsmedicales.fr/author/Diana%20Imhof",
"affiliation": {
"@type": "Organization",
"name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de."
}
},
{
"@type": "Person",
"name": "Jeremy W Jacobs",
"url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu."
}
},
{
"@type": "Person",
"name": "Jiraphorn Issara-Amphorn",
"url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn",
"affiliation": {
"@type": "Organization",
"name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Lupus anti-coagulant hypoprothrombinemia syndrome across different ages: a case report and review of the literature.",
"datePublished": "2023-05-08",
"url": "https://questionsmedicales.fr/article/37157007",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10067-023-06619-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comprehensive comparison of global coagulation assays to differentiate lupus anticoagulant from acquired hemophilia A in patients with prolonged APTT.",
"datePublished": "2023-09-26",
"url": "https://questionsmedicales.fr/article/37751038",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12185-023-03659-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Testing for Lupus Anticoagulants.",
"datePublished": "2022-06-01",
"url": "https://questionsmedicales.fr/article/35649428",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1744363"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lupus, antiphospholipid syndrome, and stroke: An attempt to crossmatch.",
"datePublished": "2023-03-20",
"url": "https://questionsmedicales.fr/article/36940089",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/09612033231165151"
}
},
{
"@type": "ScholarlyArticle",
"name": "Left ventricular size and function in patients with systemic lupus erythematosus associate with lupus anticoagulant: An echocardiographic follow-up study.",
"datePublished": "2022-08-24",
"url": "https://questionsmedicales.fr/article/36029716",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jaut.2022.102884"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Inhibiteurs des facteurs de la coagulation sanguine",
"item": "https://questionsmedicales.fr/mesh/D019774"
},
{
"@type": "ListItem",
"position": 4,
"name": "Inhibiteur lupique de la coagulation",
"item": "https://questionsmedicales.fr/mesh/D016682"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Inhibiteur lupique de la coagulation",
"description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Inhibiteur lupique de la coagulation",
"description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Inhibiteur lupique de la coagulation",
"description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Inhibiteur lupique de la coagulation",
"description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?",
"url": "https://questionsmedicales.fr/mesh/D016682#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants."
}
},
{
"@type": "Question",
"name": "Quels sont les signes cliniques associés ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente."
}
},
{
"@type": "Question",
"name": "Le diagnostic nécessite-t-il des antécédents médicaux ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants."
}
},
{
"@type": "Question",
"name": "Peut-on avoir un inhibiteur sans lupus ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'une personne à l'autre ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques aux femmes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques."
}
},
{
"@type": "Question",
"name": "Les symptômes peuvent-ils s'aggraver avec le temps ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans saignement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'inhibiteur lupique ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Quels conseils de mode de vie peuvent aider ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les femmes enceintes doivent-elles être surveillées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress pour prévenir les symptômes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Les anticoagulants sont-ils toujours nécessaires ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires aux traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections."
}
},
{
"@type": "Question",
"name": "Le traitement est-il à vie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être graves ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes d'alerte pour les complications ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux jouent-ils un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique."
}
},
{
"@type": "Question",
"name": "Le stress peut-il être un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur."
}
}
]
}
]
}
Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de.
Publications dans "Inhibiteur lupique de la coagulation" :
Translational Research in Inflammation and Immunology Research Unit (TRIRU), Department of Microbiology, Chulalongkorn University, Bangkok, Thailand, aleelahavanit@gmail.com.
Publications dans "Inhibiteur lupique de la coagulation" :
Department of Pathology and Laboratory Medicine , University of North Carolina at Chapel Hill , 819 Brinkhous-Bullitt Building , Chapel Hill , North Carolina 27599 , United States.
Publications dans "Inhibiteur lupique de la coagulation" :
Lupus anti-coagulant hypoprothrombinemia syndrome (LAHPS) is a rare condition that can be difficult to treat. It increases the risk of thrombosis and bleeding due to the presence of lupus anti-coagula...
There is no established method for differentiating acquired hemophilia A (AHA) from lupus anticoagulant (LA) positivity because both present with prolonged activated partial thromboplastin time. We co...
Lupus anticoagulant (LA) is one of the three criteria antiphospholipid antibodies (aPLs) employed in classification, and by default diagnosis, of antiphospholipid syndrome (APS). Detection of LA is no...
Cerebrovascular accidents (CVAs) or strokes are part of the common thrombotic manifestations of Systemic Lupus Erythematosus (SLEs) and Antiphospholipid syndrome (APS). Such neurological thrombotic ev...
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with increased risk of cardiac dysfunction. The pathophysiological mechanisms are poorly understood, and prognostic markers are warra...
We aimed to identify SLE-characteristics associated with measures of cardiac size and function during a five-year follow-up....
We included 108 patients with SLE: 90% females, mean age 46 ± 13 years, median disease duration 14 (range 7-21) years. We performed blood sampling for potential biomarkers as well as a standard echoca...
During follow-up, diastolic function regressed in two out of five echocardiographic measures (E/A ratio 1.4 ± 0.5 vs. 1.3 ± 0.5, p = 0.002; tricuspid regurgitation peak velocity 2.0 ± 0.6 vs. 2.2 ± 0....
Presence of LAC was associated with measures of diastolic function as well as progressive LV dilatation during the 5-year follow-up. Thus, LAC might be a predictor of cardiac dysfunction in SLE patien...
Mixing tests in activated partial thromboplastin time (APTT) are used for the differentiation between lupus anticoagulants (LA), coagulation inhibitors, and factor deficient samples with APTT prolonga...
Twenty-six LA-positive, 8 progressive coagulation factor VIII inhibitor, and 35 coagulation deficient samples were employed. APTT were measured for normal plasma, patient plasma, and mixing plasma pre...
Sensitivity and specificity to LA were 80.8% and 93.0% for ALD50, and sensitivity and specificity to progressive coagulation factor inhibitor were 100.0% and 100.0% for WaS, respectively. The agreemen...
ALD50 and WaS showed acceptable sensitivity and specificity to LA and progressive coagulation factor inhibitor, respectively. These indexes would be useful for the differentiation between LA, factor d...
Direct oral anticoagulants (DOACs) interfere with many coagulation assays, mostly in lupus anticoagulant (LA) detection, causing false positive and negative results. Despite guidelines recommendations...
In this study, the effect of activated charcoal (DOAC-Stop, DS) as a DOAC-adsorbent was investigated on samples from DOACs treated and untreated patients....
165 plasma samples with a LA request were collected in three laboratories: 105 were from patients receiving DOACs and 60 were from nonanticoagulated patients with 30 LA negative and 30 LA positive. Al...
The adsorption technique reduced DOACs concentration below the Lower Limit of Quantification. For nonanticoagulated patients: no significant difference in ratio results of coagulation screening (proth...
Our study suggests that DOAC-Stop can be used in daily laboratory practice to remove DOACs interference for a more accurate assessment of LA that is essential for diagnosis and management of APS patie...
BACKGROUND Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is an exceptionally rare disease caused by prothrombin antibodies, resulting in reduced factor II levels. This disease can present w...
Lupus anticoagulant (LA) are commonly detected during SARS-CoV-2 infection. However, the relationship between LA and clinical significance is still unclear....
A retrospective chart analysis was performed on COVID-19 patients who were tested for LA at our hospital from March 2020 to November 2021. We analyzed the patient's characteristics based on the result...
A total of 219 COVID-19 patients were enrolled in the study, 148 patients (67.6%) were positive for LA test. The LA-positive group received more treatment of high flow nasal cannula (LA-positive 73.0%...
In COVID-19 patients, LA is expected to be associated to disease severity. Since the clinical significance of LA is different depending on the onset time of LA positivity, the LA test is suggested to ...
Some reports have discussed the development of a new entity called vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination. In this case series, we are describing four patients w...